KarWaiLoh personal page - To The Moon

KarWaiLoh

No personal profile

4Follow

0Followers

0Topic

0Badge

2021-07-16

Insightful

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3585045414220324","uuid":"3585045414220324","gmtCreate":1621953376615,"gmtModify":1621953376615,"name":"KarWaiLoh","pinyin":"karwailoh","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":170542146,"gmtCreate":1626444066385,"gmtModify":1703760312874,"author":{"id":"3585045414220324","authorId":"3585045414220324","name":"KarWaiLoh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585045414220324","authorIdStr":"3585045414220324"},"themes":[],"htmlText":"Insightful","listText":"Insightful","text":"Insightful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170542146","repostId":"2151504161","repostType":4,"isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":170542146,"gmtCreate":1626444066385,"gmtModify":1703760312874,"author":{"id":"3585045414220324","authorId":"3585045414220324","name":"KarWaiLoh","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585045414220324","authorIdStr":"3585045414220324"},"themes":[],"htmlText":"Insightful","listText":"Insightful","text":"Insightful","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/170542146","repostId":"2151504161","repostType":4,"repost":{"id":"2151504161","pubTimestamp":1626437538,"share":"https://ttm.financial/m/news/2151504161?lang=&edition=fundamental","pubTime":"2021-07-16 20:12","market":"us","language":"en","title":"GSK drug shows promise in treating anaemia in kidney disease patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2151504161","media":"Reuters","summary":"July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney dis","content":"<p>July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage experimental trials, marking an important milestone for the British drugmaker as it bolsters its pipeline of new drugs.</p>\n<p>The drug, daprodustat, belongs to a new class of medicines that works by copying the body's response to hypoxia, or low oxygen levels, and boosts production of red blood cells by mimicking the body's response to high altitude.</p>\n<p>GSK said results from five late stage studies showed the drug improved haemoglobin levels in patients who had not received any standard care, and helped maintain the levels in those who did.</p>\n<p>Daprodustat was also well-tolerated in both dialysis and non-dialysis patients.</p>\n<p>A rival drug roxadustat, developed by AstraZeneca and Fibrogen, works just like GSK's treatment and won its first approval in China in late 2018, but a panel of experts to U.S. authorities voted against its approval on Thursday.</p>\n<p>GSK's daprodustat is currently approved only in Japan for use in patients with renal anaemia.</p>\n<p>Anaemia is a condition in which the number of red blood cells, or haemoglobin concentration within them, is lower than normal, and can commonly affect patients with kidney disease.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK drug shows promise in treating anaemia in kidney disease patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK drug shows promise in treating anaemia in kidney disease patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 20:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-gsk-drug-shows-promise-121218995.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage experimental trials, marking an important milestone for the British ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-gsk-drug-shows-promise-121218995.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","AZN":"阿斯利康"},"source_url":"https://finance.yahoo.com/news/1-gsk-drug-shows-promise-121218995.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2151504161","content_text":"July 16 (Reuters) - GlaxoSmithKline Plc said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage experimental trials, marking an important milestone for the British drugmaker as it bolsters its pipeline of new drugs.\nThe drug, daprodustat, belongs to a new class of medicines that works by copying the body's response to hypoxia, or low oxygen levels, and boosts production of red blood cells by mimicking the body's response to high altitude.\nGSK said results from five late stage studies showed the drug improved haemoglobin levels in patients who had not received any standard care, and helped maintain the levels in those who did.\nDaprodustat was also well-tolerated in both dialysis and non-dialysis patients.\nA rival drug roxadustat, developed by AstraZeneca and Fibrogen, works just like GSK's treatment and won its first approval in China in late 2018, but a panel of experts to U.S. authorities voted against its approval on Thursday.\nGSK's daprodustat is currently approved only in Japan for use in patients with renal anaemia.\nAnaemia is a condition in which the number of red blood cells, or haemoglobin concentration within them, is lower than normal, and can commonly affect patients with kidney disease.","news_type":1},"isVote":1,"tweetType":1,"viewCount":24,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}